Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1987 1
1988 3
1989 3
1990 2
1991 2
1992 2
1993 6
1994 4
1995 2
1996 1
1997 3
1998 2
1999 3
2000 2
2001 1
2002 4
2003 5
2004 3
2005 2
2007 1
2008 1
2009 3
2010 6
2011 3
2012 2
2013 2
2014 4
2015 3
2017 4
2018 4
2019 4
2020 2
2021 4
2022 2
Text availability
Article attribute
Article type
Publication date

Search Results

88 results
Results by year
Filters applied: . Clear all
Page 1
Comprehensive characterization of 536 patient-derived xenograft models prioritizes candidatesfor targeted treatment.
Sun H, Cao S, Mashl RJ, Mo CK, Zaccaria S, Wendl MC, Davies SR, Bailey MH, Primeau TM, Hoog J, Mudd JL, Dean DA 2nd, Patidar R, Chen L, Wyczalkowski MA, Jayasinghe RG, Rodrigues FM, Terekhanova NV, Li Y, Lim KH, Wang-Gillam A, Van Tine BA, Ma CX, Aft R, Fuh KC, Schwarz JK, Zevallos JP, Puram SV, Dipersio JF; NCI PDXNet Consortium, Davis-Dusenbery B, Ellis MJ, Lewis MT, Davies MA, Herlyn M, Fang B, Roth JA, Welm AL, Welm BE, Meric-Bernstam F, Chen F, Fields RC, Li S, Govindan R, Doroshow JH, Moscow JA, Evrard YA, Chuang JH, Raphael BJ, Ding L. Sun H, et al. Among authors: moscow ja. Nat Commun. 2021 Aug 24;12(1):5086. doi: 10.1038/s41467-021-25177-3. Nat Commun. 2021. PMID: 34429404 Free PMC article.
Conservation of copy number profiles during engraftment and passaging of patient-derived cancer xenografts.
Woo XY, Giordano J, Srivastava A, Zhao ZM, Lloyd MW, de Bruijn R, Suh YS, Patidar R, Chen L, Scherer S, Bailey MH, Yang CH, Cortes-Sanchez E, Xi Y, Wang J, Wickramasinghe J, Kossenkov AV, Rebecca VW, Sun H, Mashl RJ, Davies SR, Jeon R, Frech C, Randjelovic J, Rosains J, Galimi F, Bertotti A, Lafferty A, O'Farrell AC, Modave E, Lambrechts D, Ter Brugge P, Serra V, Marangoni E, El Botty R, Kim H, Kim JI, Yang HK, Lee C, Dean DA 2nd, Davis-Dusenbery B, Evrard YA, Doroshow JH, Welm AL, Welm BE, Lewis MT, Fang B, Roth JA, Meric-Bernstam F, Herlyn M, Davies MA, Ding L, Li S, Govindan R, Isella C, Moscow JA, Trusolino L, Byrne AT, Jonkers J, Bult CJ, Medico E, Chuang JH; PDXNET Consortium; EurOPDX Consortium. Woo XY, et al. Among authors: moscow ja. Nat Genet. 2021 Jan;53(1):86-99. doi: 10.1038/s41588-020-00750-6. Epub 2021 Jan 7. Nat Genet. 2021. PMID: 33414553 Free PMC article.
Multidrug resistance.
Moscow JA, Cowan KH. Moscow JA, et al. J Natl Cancer Inst. 1988 Mar 2;80(1):14-20. doi: 10.1093/jnci/80.1.14. J Natl Cancer Inst. 1988. PMID: 2892943 Review.
The evidence framework for precision cancer medicine.
Moscow JA, Fojo T, Schilsky RL. Moscow JA, et al. Nat Rev Clin Oncol. 2018 Mar;15(3):183-192. doi: 10.1038/nrclinonc.2017.186. Epub 2017 Dec 19. Nat Rev Clin Oncol. 2018. PMID: 29255239 Review.
Steps forward for cancer precision medicine.
Salgado R, Moore H, Martens JWM, Lively T, Malik S, McDermott U, Michiels S, Moscow JA, Tejpar S, McKee T, Lacombe D; IBCD-Faculty. Salgado R, et al. Among authors: moscow ja. Nat Rev Drug Discov. 2018 Jan;17(1):1-2. doi: 10.1038/nrd.2017.218. Epub 2017 Nov 24. Nat Rev Drug Discov. 2018. PMID: 29170471
Methotrexate transport and resistance.
Moscow JA. Moscow JA. Leuk Lymphoma. 1998 Jul;30(3-4):215-24. doi: 10.3109/10428199809057535. Leuk Lymphoma. 1998. PMID: 9713954 Review.
Glutathione S-transferase and drug resistance.
Cazenave LA, Moscow JA, Myers CE, Cowan KH. Cazenave LA, et al. Among authors: moscow ja. Cancer Treat Res. 1989;48:171-87. doi: 10.1007/978-1-4613-1601-5_11. Cancer Treat Res. 1989. PMID: 2577137 Review.
Author Correction: Conservation of copy number profiles during engraftment and passaging of patient-derived cancer xenografts.
Woo XY, Giordano J, Srivastava A, Zhao ZM, Lloyd MW, de Bruijn R, Suh YS, Patidar R, Chen L, Scherer S, Bailey MH, Yang CH, Cortes-Sanchez E, Xi Y, Wang J, Wickramasinghe J, Kossenkov AV, Rebecca VW, Sun H, Mashl RJ, Davies SR, Jeon R, Frech C, Randjelovic J, Rosains J, Galimi F, Bertotti A, Lafferty A, O'Farrell AC, Modave E, Lambrechts D, Ter Brugge P, Serra V, Marangoni E, El Botty R, Kim H, Kim JI, Yang HK, Lee C, Dean DA 2nd, Davis-Dusenbery B, Evrard YA, Doroshow JH, Welm AL, Welm BE, Lewis MT, Fang B, Roth JA, Meric-Bernstam F, Herlyn M, Davies MA, Ding L, Li S, Govindan R, Isella C, Moscow JA, Trusolino L, Byrne AT, Jonkers J, Bult CJ, Medico E, Chuang JH; PDXNET Consortium; EurOPDX Consortium. Woo XY, et al. Among authors: moscow ja. Nat Genet. 2021 May;53(5):761. doi: 10.1038/s41588-021-00811-4. Nat Genet. 2021. PMID: 33608693 Free PMC article. No abstract available.
Phase IB Study of Osimertinib in Combination with Navitoclax in EGFR-mutant NSCLC Following Resistance to Initial EGFR Therapy (ETCTN 9903).
Bertino EM, Gentzler RD, Clifford S, Kolesar J, Muzikansky A, Haura EB, Piotrowska Z, Camidge DR, Stinchcombe TE, Hann C, Malhotra J, Villaruz LC, Paweletz CP, Lau CL, Sholl L, Takebe N, Moscow JA, Shapiro GI, Jänne PA, Oxnard GR. Bertino EM, et al. Among authors: moscow ja. Clin Cancer Res. 2021 Mar 15;27(6):1604-1611. doi: 10.1158/1078-0432.CCR-20-4084. Epub 2020 Dec 29. Clin Cancer Res. 2021. PMID: 33376097 Free PMC article. Clinical Trial.
88 results